Abeona Therapeutics (ABEO) Issues Quarterly Earnings Results
Abeona Therapeutics (NASDAQ:ABEO) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.11), Zacks reports. The business had revenue of $1.71 million for the quarter, compared to analysts’ expectations of $1.02 million. Abeona Therapeutics had a negative net margin of 843.14% and a negative return on equity of 27.01%.
Shares of ABEO opened at $7.71 on Tuesday. Abeona Therapeutics has a twelve month low of $7.70 and a twelve month high of $22.00. The stock has a market cap of $448.75 million, a PE ratio of -11.68 and a beta of 1.77.
Several research firms have commented on ABEO. Cantor Fitzgerald set a $36.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Monday. BidaskClub downgraded shares of Abeona Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, November 8th. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 17th. HC Wainwright set a $30.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Friday, July 27th. Finally, ValuEngine raised shares of Abeona Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $25.90.
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Story: Insider Trading – What You Need to Know
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.